Show source-provided references
2. Polymeric drug delivery systems
6. Solvent-adaptable poly (vinylpyrrolidone) binding induced anisotropic shape control of gold nanostructures
10.1021/jp306952d ↗10. Optimizing Oral Bioavailability in Drug Discovery: An Overview of Design and Testing Strategies and Formulation Options
10.1016/j.xphs.2016.12.002 ↗11. Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults
10.1128/AAC.00400-20 ↗12. Increased oral bioavailability of itraconazole and its active metabolite, 7-hydroxyitraconazole, when coadministered with a vitamin C beverage in healthy participants
10.1177/0091270010365557 ↗14. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system
10.1007/s11095-004-9004-4 ↗15. A review on electrospun nanofibers for oral drug delivery
17. A comprehensive review summarizing the effect of electrospinning parameters and potential applications of nanofibers in biomedical and biotechnology
10.1016/j.arabjc.2015.11.015 ↗19. Modeling and process optimization of electrospinning of chitosan-collagen nanofiber by response surface methodology
10.1088/2053-1591/aaba1d ↗21. Indomethacin electrospun nanofibers for colonic drug delivery: Preparation and characterization
22. Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning
10.1023/A:1023450006281 ↗23. Comparison of spray drying, electroblowing and electrospinning for preparation of Eudragit E and itraconazole solid dispersions
10.1016/j.ijpharm.2015.07.076 ↗25. Lubricant-Induced Crystallization of Itraconazole From Tablets Made of Electrospun Amorphous Solid Dispersion
10.1016/j.xphs.2016.04.032 ↗26. Preparation and functional evaluation of electrospun polymeric nanofibers as a new system for sustained topical ocular delivery of itraconazole
10.1080/10837450.2021.2018609 ↗29. Recent development and achievements in solubility and dissolution enhancement of itraconazole: A review
30. Pintea, A., Vlad, R.-A., Antonoaea, P., Rédai, E.M., Todoran, N., Barabás, E.-C., and Ciurba, A. (2022). Structural Characterization and Optimization of a Miconazole Oral Gel. Polymers, 14.
10.3390/polym14225011 ↗31. Vlad, R.-A., Antonoaea, P., Todoran, N., Rédai, E.-M., Bîrsan, M., Muntean, D.-L., Imre, S., Hancu, G., Farczádi, L., and Ciurba, A. (2022). Development and evaluation of cannabidiol orodispersible tablets using a 23-factorial design. Pharmaceutics, 14.
10.3390/pharmaceutics14071467 ↗32. Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability
10.1208/s12249-015-0332-y ↗43. Formula comparison of nanoemulsion and cream containing miconazole nitrate: Penetration test using franz diffusion cells and antifungal activity test on Tricophyton mentagrophytes, Microsporum canis and Candida albicans
10.31788/RJC.2020.1315553 ↗44. Antifungal efficacy of itraconazole-loaded TPGS-b-(PCL-ran-PGA) nanoparticles